Cite
HARVARD Citation
Rugo, H. et al. (2023). Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial. Journal of clinical oncology. 41 (2), pp. 198-205. [Online].